Ligand Pharmaceuticals Inc (LGND) director Jason Aryeh reported a proposed sale of 282 Class B common shares, with an aggregate market value of $90,225.50. The notice lists Nasdaq as the exchange and November 4, 2026, as the approximate sale date.
The notice identifies the shares as a secondary-market purchase and remarks that they were acquired between May 14, 2019, and July 30, 2019. It also lists prior sales by Aryeh: 1,209 shares for $385,185.47 and 202 shares for $64,738.00 on October 30, 2026, and 700 shares for $221,595.09 on November 2, 2026.
Andrew Reardon, Ligand Pharmaceuticals’ CLO & Secretary, exercised employee stock options for 5,000 common shares at a $52.27 exercise price on November 2, 2026, and sold 5,000 shares across 13 reported sales. The transactions were made under a written Rule 10b5-1 trading plan adopted June 4, 2026. Reardon held 24,104 employee stock options following the exercise.
Ligand Pharmaceuticals Inc. (LGND) director Jason Aryeh reported six direct sales of 2,111 common shares: five transactions on October 30, 2026, at $317.7400, $318.2300, $320.2400, $320.4172 and $320.4900 per share, and 700 shares on November 2 at a weighted-average $320.4261 per share. The November 2 shares were sold in multiple transactions at prices ranging from $320.39 to $320.49. The report also lists 8,000 shares held indirectly by funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates; Aryeh is identified as general partner of JALAA Equities and a partner of JLV Investments.
Ligand Pharmaceuticals Inc. (LGND) director Jason Aryeh filed a notice of intent to sell 700 shares of Class B common stock, with an aggregate market value of $221,595.09 and an approximate sale date of November 2, 2026.
Ligand Pharmaceuticals Incorporated (LGND) completed its acquisition of XOMA Royalty Corporation on July 14, 2026, for a preliminary purchase price of $887.0 million. Consideration included $833.5 million in cash paid upon acquisition, including $691.7 million for XOMA Royalty common stock at $39.00 per share; the remaining $53.5 million related to XOMA equity awards. The acquired portfolio included seven commercial products, 14 late-stage development programs and more than 100 other assets in development.
For the third quarter, total revenues and income were $78.7 million, compared with $115.5 million a year earlier; royalties rose to $70.3 million from $46.6 million. The prior-year quarter included $53.1 million of income from the Pelthos transaction. Ligand recorded a $28.5 million net loss, versus $117.3 million net income, including a $35.7 million loss from changes in fair value of equity-method and other investments. For the first nine months, operating cash flow was $45.1 million, compared with $3.4 million. At September 30, 2026, cash and cash equivalents were $56.0 million and short-term investments were $391.4 million.
Ligand Pharmaceuticals Inc. director Jason M. Aryeh reported a proposed sale of 1,209 common shares, with an aggregate market value of $385,185.47 and an approximate sale date of October 30, 2026. The sale details name Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are identified as restricted stock acquired from the issuer on June 5, 2026.
Ligand Pharmaceuticals Inc. (LGND) director Jason M. Aryeh reported a planned sale of 202 common shares through Charles Schwab & Co., Inc., with an aggregate market value of $64,738.00 and an approximate sale date of October 30, 2026. The notice lists the shares as acquired in an open-market purchase on March 13, 2019, with cash payment.
Ligand Pharmaceuticals Incorporated reported third-quarter 2026 royalty revenue of $70.3 million, up 51% year over year from $46.6 million; royalties were 89% of total revenues and income. Total revenues and income were $78.7 million, down 32% from $115.5 million, as the prior-year quarter included $53.1 million of Pelthos divestiture-related income; excluding that item, total revenues and income increased 26%. Captisol sales were $7.9 million versus $10.7 million.
GAAP results were a $28.5 million net loss, versus $117.3 million net income a year earlier; third-quarter results included $39.5 million of pre-tax investment losses. Adjusted net income was $57.5 million, down 10%, and adjusted earnings per diluted share were $2.67, down 14%. General and administrative expense was $72.6 million versus $28.4 million, reflecting XOMA transaction and integration costs, share-based compensation and higher employee-related costs. Ligand raised full-year 2026 adjusted diluted EPS guidance to $9.50–$9.75 from $9.00–$9.50 and reaffirmed revenue guidance.
Ligand Pharmaceuticals (LGND) Chief Legal Officer and Secretary Andrew Reardon exercised 340 employee stock options on October 2, 2026, at a $52.27 exercise price, acquiring 340 common shares; 29,104 options remained after the exercise. That day, he sold 5,000 common shares in six transactions under a written Rule 10b5-1 plan adopted June 4, 2026. Five sale blocks carried weighted-average prices of $302.5107 (833 shares), $303.5444 (1,976 shares), $304.5154 (1,535 shares), $306.1834 (404 shares), and $307.1911 (235 shares); another 17 shares were reported at $307.7400.
Ligand Pharmaceuticals Inc. director Martine Zimmermann had 115 shares withheld by the issuer on September 22, 2026, to pay tax liability arising from restricted stock unit settlement. The reported price was $298.50 per share, and Zimmermann’s direct holdings after the transaction were 3,782 shares. No Rule 10b5-1 plan is reported.